Zhang, Yanchao
Bailey, Tom S.
Hittmeyer, Philip
Dubois, Ludwig J.
Theys, Jan
Lambin, Philippe
Funding for this research was provided by:
China Scholarships Council (202000670035)
KWF-Alpe d’HuZes (13056, 13056, 13056, 13056)
ERC Adv (694812-Hypoximmuno)
ERC PoC (813200-CL-IO)
Article History
Received: 13 February 2024
Accepted: 11 April 2024
First Online: 24 April 2024
Declarations
:
: Not applicable.
: Not applicable.
: P.L. reports, within and outside the submitted work, presenter fees and/or reimbursement of travel costs or consultancy fees and/or in-kind contributions from Benelux Health Ventures, Roche, Convert Pharmaceuticals, and LivingMed Biotech. P.L. has minority shares in the companies LivingMed Biotech, Comunicare, Radiomics SA, Bactam, and Convert Pharmaceutical. L.J.D. reports, within and outside the submitted work, minority shares in LivingMed Biotech and Convert Pharmaceuticals. J.T. reports, within and outside the submitted work, minority shares in Convert Pharmaceuticals. P.H. was an employee of LivingMed Biotech in 2021 and 2022. T.S.B. was an employee of LivingMed Biotech for 3 months in 2020.